Why do people with Post-Orgasmic Illness Syndrome (POIS) develop symptoms such as fatigue, brain fog, muscle pain, nasal congestion, or flu-like symptoms after ejaculation or orgasm? The underlying cause of this rare condition remains unknown.
Since the first scientific descriptions of POIS, researchers have repeatedly discussed a possible involvement of the immune system. Proposed mechanisms have included allergy-like reactions to components of a person’s own semen, inflammatory processes, and the release of various immune mediators.
A new scientific review now focuses specifically on mast cells, histamine, immunoglobulins, and systemic inflammatory responses. Authors James G. Pfaus and Alyssa Yee examine whether these mechanisms could help explain why POIS can cause symptoms affecting such a wide range of organ systems following orgasm or ejaculation.
One important limitation should be made clear from the outset: the paper does not provide new experimental evidence that mast cells cause POIS. It is a narrative review in which the authors bring together existing POIS research with findings on mast cells, histamine, immune responses, and inflammatory processes to develop possible explanatory models.
What are mast cells?
Mast cells are part of the immune system and are found in tissues including the skin and mucous membranes, as well as near blood vessels and nerves. They are also present in the urogenital tract. When activated, mast cells can release a wide range of biologically active substances, including histamine, tryptase, prostaglandins, and other inflammatory mediators.
They are particularly well known for their role in allergic reactions. However, mast cells are not involved exclusively in classical allergies. Their activation can influence a variety of inflammatory and immune processes, and the mediators they release may have effects beyond the original site of activation.
This makes mast cells potentially relevant to POIS because some commonly reported symptoms resemble allergic or inflammatory reactions, including a runny or blocked nose, irritated eyes, skin symptoms, headaches, and general flu-like symptoms.
However, POIS also commonly involves pronounced fatigue, brain fog, concentration difficulties, muscle symptoms, and mood changes, with symptoms potentially lasting for hours or several days.
More than a simple histamine reaction?
This distinction plays an important role in the new review.
Pfaus and Yee argue that the overall POIS symptom pattern cannot be adequately explained by a simple acute histamine intolerance alone. In their interpretation, POIS more closely resembles a complex inflammatory response involving multiple organ systems. Among the reasons they discuss are the prolonged duration of symptoms and the cognitive and neuropsychiatric manifestations of POIS.
The authors consider several possible ways in which such a response might develop.
In some people with POIS, a sensitized immune response to components of seminal fluid might be involved. In others, orgasm or ejaculation might activate mast cells through different pathways, potentially leading to the release of inflammatory mediators.
The authors also discuss whether a history of allergies or atopic conditions may be relevant in a subset of people with POIS.
Importantly, however, these are proposed mechanisms rather than evidence of a single established cause of POIS.
What role could immunoglobulins play?
Another major focus of the review is immunoglobulins, or antibodies produced by the immune system.
Particular attention is given to immunoglobulin E (IgE), which plays an important role in many allergic reactions. This discussion is partly based on earlier POIS research. In a well-known study by Marcel Waldinger and colleagues, 29 of 33 men with POIS who underwent skin testing reacted to their own semen.
The authors therefore discuss whether an immune sensitization to components of a person’s own semen could contribute to POIS in at least some patients. Potential triggers discussed include components of seminal fluid, proteins associated with sperm, and prostate-derived or other immunologically active substances.
However, a simple “allergy to one’s own semen” cannot explain POIS in general.
There are several reasons for this. Previous studies have not produced a consistent picture regarding IgE-mediated reactions. In addition, Pfaus and Yee point out that POIS has also been reported in women, including symptoms following orgasm during masturbation or sexual activity without exposure to male semen. An antigen in a person’s own semen cannot account for such cases.
The authors also distinguish POIS from hypersensitivity to human seminal plasma. In particular, the cognitive or neuropsychiatric symptoms characteristic of POIS and its typical time course are not characteristic features of classical seminal plasma hypersensitivity.
The review therefore goes beyond the idea of a simple “semen allergy” and considers a broader range of possible immune and inflammatory processes.
Omalizumab as a clue to a possible IgE-mediated mechanism?
The authors devote particular attention to two published case reports in which patients with POIS were treated with omalizumab (Xolair).
Omalizumab is a monoclonal antibody that binds free IgE and thereby modifies IgE-mediated responses involving cells such as mast cells and basophils.
In both case reports, complete resolution of POIS symptoms was reported with monthly injections of 300 mg omalizumab. Interestingly, however, the patients’ immunological findings were different.
One patient had elevated baseline IgE levels while skin testing with his own semen was negative. In the second patient, baseline IgE was not elevated above the normal range, and the report did not establish that skin testing with his own semen was positive.
The authors interpret these observations as a possible indication that IgE- and mast-cell-related mechanisms may be involved in certain people with POIS. At the same time, the differing findings show that even these cases cannot simply be explained by an IgE-mediated reaction to a person’s own semen.
Most importantly, two case reports are not sufficient to establish the effectiveness of omalizumab for POIS or to demonstrate a specific IgE-mediated disease mechanism.
The authors therefore explicitly call for larger, placebo-controlled, double-blind trials to systematically investigate omalizumab in POIS.
What can previous treatment experiences tell us?
In addition to omalizumab, Pfaus and Yee consider reports involving a range of other treatment approaches.
The POIS literature has described the use of H1 and H2 antihistamines, leukotriene antagonists, corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs), among other approaches. Hyposensitization using increasing concentrations of autologous semen has also been investigated in individual patients.
The authors regard these differing treatment responses as potential clues to underlying mechanisms. At the same time, they highlight a fundamental problem in POIS research: a treatment that appears helpful for one person may not work for another.
Much of the available evidence on POIS treatments comes from individual case reports or small case series. This makes it difficult to infer an underlying disease mechanism from an observed improvement.
For example, if an antihistamine reduces symptoms in some patients, this does not automatically mean that histamine is the cause of POIS. Similarly, the omalizumab cases do not establish that POIS is generally an IgE-mediated disorder.
The varying treatment responses may instead provide another indication that the biological mechanisms underlying POIS may not be identical in all affected individuals.
This possible heterogeneity is also consistent with a recent study that identified four possible POIS phenotypes based on different symptom patterns.
A possible model – but not evidence that POIS is MCAS
Mast Cell Activation Syndrome (MCAS) also receives considerable attention in the review.
It is important, however, to distinguish between the possible involvement of mast cells and an actual diagnosis of MCAS.
Pfaus and Yee describe different approaches to defining MCAS. Under more stringent consensus criteria, diagnosis includes recurrent symptoms affecting multiple organ systems together with objective evidence of changes in specific mast-cell mediators during symptomatic episodes. Other proposed criteria define MCAS more broadly.
The authors themselves note that many people with POIS have either not been tested for relevant mast-cell markers or do not meet the more stringent diagnostic criteria.
The review therefore should not be interpreted as evidence that POIS is a form of MCAS or that people with POIS generally have MCAS.
Instead, the authors explore whether known mechanisms of mast-cell activation might provide a model for understanding how orgasm or ejaculation could trigger symptoms across multiple organ systems in at least some people with POIS.
Whether this actually occurs needs to be investigated experimentally.
Stress and conditioned immune responses
A more speculative part of the review considers whether stress and learned or conditioned immune responses could influence symptoms in some people with POIS.
This discussion is based on known interactions between the nervous system, stress responses, and the immune system. The authors consider whether repeatedly experiencing pronounced symptoms after orgasm or ejaculation could potentially lead the expectation of those symptoms to activate certain stress and immune responses.
This does not mean that POIS is being described as a purely psychological condition. Rather, the authors discuss a possible interaction between the sympathetic nervous system and immune system through which an existing physiological response might potentially be amplified.
Whether such a mechanism actually occurs in POIS is currently unknown. The authors note that it has not yet been established whether anticipating POIS symptoms before or during sexual activity changes the threshold for inflammatory responses or influences histamine release.
What does the review mean for POIS research?
The review does not provide a new treatment or a biomarker that can be used to diagnose POIS. Nor does it demonstrate that mast cells, histamine, or any particular immune response is the cause of the syndrome.
Its main value lies in bringing together a number of previously discussed observations within a broader immunological framework.
One particularly interesting possibility is that the same mechanism may not be responsible for POIS in every affected person. Immune sensitization or mast-cell-related mechanisms could be more relevant in some individuals, while other processes may predominate in others.
This could potentially help explain both the highly variable presentation of POIS and why no single treatment approach has so far worked consistently across patients.
To investigate these hypotheses, Pfaus and Yee call for studies systematically comparing immune, endocrine, and other physiological parameters in people with POIS and matched healthy controls before and after orgasm or ejaculation.
The authors also refer to an ongoing POIS research study investigating such mechanisms. In addition, they call for controlled trials of omalizumab and further investigation of the different time courses between orgasm or ejaculation and the onset of POIS symptoms.
Conclusion
The new review by James G. Pfaus and Alyssa Yee places mast cells, immunoglobulins, and systemic inflammatory responses at the center of a possible model of POIS pathophysiology.
According to the authors, the complex symptom pattern of POIS – which can persist for several days – cannot be adequately explained by a simple histamine reaction alone. Instead, they discuss a more complex interaction between different immune and inflammatory processes that may vary from one person with POIS to another.
The published omalizumab case reports and the overlap between POIS symptoms and known mast-cell and histamine mechanisms are particularly interesting. However, these observations provide clues and hypotheses, not proof.
There is currently no evidence that POIS is generally caused by mast-cell activation, nor does the review establish that POIS is a form of MCAS or a classical allergy to a person’s own semen.
Controlled studies comparing people with POIS with healthy participants will be needed to determine what roles mast cells, histamine, immunoglobulins, and other inflammatory mediators actually play.
The review therefore provides something particularly valuable for future POIS research: specific biological mechanisms that can now be investigated more systematically.